getimage-48-768x274.png
Capricor Therapeutics Announces Statistically Significant Clinical Benefits in Skeletal Muscle Function in Non-Ambulant Duchenne Muscular Dystrophy Patients Treated with CAP-1002 in HOPE-2 Open Label Extension Study
June 27, 2022 07:00 ET | Capricor Therapeutics
-Met Primary Endpoint of Performance of the Upper Limb PUL 2.0 (p=0.02)- -Results Suggest Disease Modification in DMD and Long-term Safety of CAP-1002- -Results were Presented at Late Breaking...
getimage-48-768x274.png
Capricor Therapeutics to Present One-Year Efficacy Results from its Ongoing HOPE-2 Open Label Extension Study at 2022 Parent Project Muscular Dystrophy Annual Conference
June 17, 2022 09:00 ET | Capricor Therapeutics
SAN DIEGO, June 17, 2022 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the...
getimage-48-768x274.png
Capricor Therapeutics Appoints Xavier Avat as Chief Business Officer
May 25, 2022 09:00 ET | Capricor Therapeutics
Capricor Expands Senior Management Team to Build Commercial Strategy for Lead Asset, CAP-1002, and Further Develop Partnering Strategy for Proprietary Exosome Platform Formerly at Edwards...
getimage-48-768x274.png
Capricor Therapeutics to Present at the H.C. Wainwright Global Investment Conference
May 18, 2022 09:00 ET | Capricor Therapeutics
SAN DIEGO, May 18, 2022 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the...
getimage-48-768x274.png
Capricor Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update
May 10, 2022 16:01 ET | Capricor Therapeutics
-Executed Partnership with Nippon Shinyaku for the Commercialization and Distribution of CAP-1002 for Duchenne Muscular Dystrophy in the United States- -Upfront Payment of $30 Million Received in...
getimage-48-768x274.png
Capricor Therapeutics to Present First Quarter 2022 Financial Results and Recent Corporate Update on May 10
May 03, 2022 08:30 ET | Capricor Therapeutics
SAN DIEGO, May 03, 2022 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the...
getimage-48-768x274.png
Capricor Therapeutics to Participate in the Cantor Fitzgerald Rare Orphan Disease Summit
March 29, 2022 09:00 ET | Capricor Therapeutics
SAN DIEGO, March 29, 2022 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR) a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the...
getimage-48-768x274.png
Capricor Therapeutics Reports Topline Results from Phase 2 Exploratory INSPIRE Trial in Severe Hospitalized COVID-19 Patients
March 28, 2022 08:30 ET | Capricor Therapeutics
-Primary Objective of Study Met: CAP-1002 was Safe and Well Tolerated- SAN DIEGO, March 28, 2022 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the...
getimage-48-768x274.png
The Lancet Publishes Positive Results from Capricor Therapeutics’ Phase 2 Study Evaluating CAP-1002 in Late-Stage Duchenne Muscular Dystrophy
March 11, 2022 08:00 ET | Capricor Therapeutics
-One-Year Final Data Highlights Lead Cell Therapy Asset, CAP-1002, for Safety and Efficacy in Slowing Upper Limb and Cardiac Function Deterioration in Patients- -Data Sets Stage for Pivotal Phase 3...
getimage-48-768x274.png
Capricor Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
March 10, 2022 16:01 ET | Capricor Therapeutics
CAP-1002 Cell Therapy Programs -Pivotal Phase 3, HOPE-3 Trial Initiation Underway- -Entered Exclusive Partnership with Nippon Shinyaku for Commercialization and Distribution of CAP-1002 for...